Related Experiment Videos
CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity
1Department of Surgery, Medical University of South Carolina, Charleston 29425.
Transplantation
|November 27, 1994
Summary
CTLA4Ig, a fusion protein, prolongs cardiac allograft survival by preventing T cell costimulation. Its effectiveness depends on administration timing during the immune response priming phase.
Area of Science:
- Immunology
- Transplantation immunology
- Molecular immunology
Background:
- T cell activation requires TCR/CD3 signaling and costimulation.
- Blocking costimulatory pathways can induce T cell anergy.
- CTLA4Ig targets B7/BB1 ligands, inhibiting CD28 and CTLA4 interactions.
Purpose of the Study:
- To investigate the immunosuppressive effects of CTLA4Ig in murine models.
- To determine the optimal timing for CTLA4Ig administration.
- To assess CTLA4Ig's impact on cell-mediated immunity and T cell responses.
Main Methods:
- Murine nonvascularized heterotopic cardiac transplant model.
- Cell-mediated immunity model using hapten TNP.
- In vivo and in vitro assays for T cell responses (CTL, MLR, proliferation, cytokine production).
- Flow cytometry for T cell subpopulation analysis.
Main Results:
- CTLA4Ig administration at transplantation significantly prolonged allograft survival.
- Early administration during immune priming was crucial for efficacy.
- CTLA4Ig suppressed contact sensitivity and secondary CTL generation.
- In vitro, CTLA4Ig inhibited MLR and T cell proliferation/cytokine responses but not primary CTL.
- No changes in T cell subpopulation distribution were observed.
Conclusions:
- CTLA4Ig demonstrates significant immunosuppressive activity in vivo.
- Both CD4+ and CD8+ T cells are suppressed by CTLA4Ig.
- Optimal therapeutic window for CTLA4Ig is during the initial immune response priming.